Do analysts recommend CCM or ACON?

Aclarion has a consensus price target of $7.50, indicating a potential upside of 108.91%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than Concord Medical Services. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, CCM or ACON?

Aclarion has lower revenue, but higher earnings than Concord Medical Services. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Concord Medical Services $65.85M 0.31 -$13.27M N/A N/A Aclarion $80K 110.39 -$7.23M -$9.03 N/A

Do analysts rate ACON or BMGL?

Aclarion presently has a consensus target price of $7.50, suggesting a potential upside of 108.91%. Given Aclarion's stronger consensus rating and higher possible upside, equities research analysts clearly believe Aclarion is more favorable than Basel Medical Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, ACON or BMGL?

Aclarion has higher earnings, but lower revenue than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aclarion $80K 110.39 -$7.23M -$9.03 N/A Basel Medical Group $8.90M 1.18 -$9.50M N/A N/A

Does the media prefer ACON or BMGL?

In the previous week, Aclarion had 15 more articles in the media than Basel Medical Group. MarketBeat recorded 16 mentions for Aclarion and 1 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 1.43 beat Aclarion's score of 0.99 indicating that Basel Medical Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclarion 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Basel Medical Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MRAI or ACON?

Aclarion has a consensus price target of $7.50, indicating a potential upside of 108.91%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, MRAI or ACON?

Aclarion has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 0.44 -$28.75M -$0.87 N/A Aclarion $80K 110.39 -$7.23M -$9.03 N/A

Is MRAI or ACON more profitable?

Marpai has a net margin of -85.70% compared to Aclarion's net margin of -10,320.51%. Marpai's return on equity of 0.00% beat Aclarion's return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Aclarion -10,320.51% -54.41% -51.71%

Do analysts rate MGRX or ACON?

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 108.91%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Mangoceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is MGRX or ACON more profitable?

Mangoceuticals has a net margin of -4,639.13% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mangoceuticals -4,639.13% -112.00% -104.96% Aclarion -10,320.51% -54.41% -51.71%

Does the media favor MGRX or ACON?

In the previous week, Aclarion had 14 more articles in the media than Mangoceuticals. MarketBeat recorded 16 mentions for Aclarion and 2 mentions for Mangoceuticals. Aclarion's average media sentiment score of 0.99 beat Mangoceuticals' score of 0.63 indicating that Aclarion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mangoceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclarion 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ACON or ADVB?

Aclarion presently has a consensus target price of $7.50, indicating a potential upside of 108.91%. Given Aclarion's stronger consensus rating and higher probable upside, research analysts clearly believe Aclarion is more favorable than Advanced Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Advanced Biomed 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Aclarion (ACON) Competitors

$3.59 +0.10 (+2.87%)

As of 01:55 PM Eastern

Compare

ACON vs. CCM, BMGL, MRAI, MGRX, and ADVB

Should you buy Aclarion stock or one of its competitors? MarketBeat compares Aclarion with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aclarion include Concord Medical Services (CCM), Basel Medical Group (BMGL), Marpai (MRAI), Mangoceuticals (MGRX), and Advanced Biomed (ADVB). These companies are all part of the "healthcare" industry.

How does Aclarion compare to Concord Medical Services?

Concord Medical Services (NYSE:CCM) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Aclarion has lower revenue, but higher earnings than Concord Medical Services.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concord Medical Services	$65.85M	0.31	-$13.27M	N/A	N/A
Aclarion	$80K	110.39	-$7.23M	-$9.03	N/A

Concord Medical Services has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Aclarion has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

7.5% of Aclarion shares are owned by institutional investors. 46.5% of Concord Medical Services shares are owned by insiders. Comparatively, 0.0% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Aclarion had 16 more articles in the media than Concord Medical Services. MarketBeat recorded 16 mentions for Aclarion and 0 mentions for Concord Medical Services. Aclarion's average media sentiment score of 0.99 beat Concord Medical Services' score of -0.16 indicating that Aclarion is being referred to more favorably in the news media.

Company	Overall Sentiment
Concord Medical Services	Neutral
Aclarion	Positive

Aclarion has a consensus price target of $7.50, indicating a potential upside of 108.91%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than Concord Medical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Concord Medical Services has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. Concord Medical Services' return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Concord Medical Services	N/A	N/A	N/A
Aclarion	-10,320.51%	-54.41%	-51.71%

Summary

Aclarion beats Concord Medical Services on 9 of the 14 factors compared between the two stocks.

How does Aclarion compare to Basel Medical Group?

Aclarion (NASDAQ:ACON) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Aclarion had 15 more articles in the media than Basel Medical Group. MarketBeat recorded 16 mentions for Aclarion and 1 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 1.43 beat Aclarion's score of 0.99 indicating that Basel Medical Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Basel Medical Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclarion presently has a consensus target price of $7.50, suggesting a potential upside of 108.91%. Given Aclarion's stronger consensus rating and higher possible upside, equities research analysts clearly believe Aclarion is more favorable than Basel Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.5% of Aclarion shares are held by institutional investors. 0.0% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aclarion has higher earnings, but lower revenue than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	110.39	-$7.23M	-$9.03	N/A
Basel Medical Group	$8.90M	1.18	-$9.50M	N/A	N/A

Aclarion has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Basel Medical Group has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. Basel Medical Group's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Basel Medical Group	N/A	N/A	N/A

Summary

Aclarion beats Basel Medical Group on 9 of the 14 factors compared between the two stocks.

How does Aclarion compare to Marpai?

Marpai (NASDAQ:MRAI) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Aclarion has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.44	-$28.75M	-$0.87	N/A
Aclarion	$80K	110.39	-$7.23M	-$9.03	N/A

In the previous week, Aclarion had 16 more articles in the media than Marpai. MarketBeat recorded 16 mentions for Aclarion and 0 mentions for Marpai. Aclarion's average media sentiment score of 0.99 beat Marpai's score of 0.74 indicating that Aclarion is being referred to more favorably in the news media.

Company	Overall Sentiment
Marpai	Positive
Aclarion	Positive

49.8% of Marpai shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 46.1% of Marpai shares are held by company insiders. Comparatively, 0.0% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Marpai has a beta of 4.94, meaning that its share price is 394% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Aclarion has a consensus price target of $7.50, indicating a potential upside of 108.91%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Marpai has a net margin of -85.70% compared to Aclarion's net margin of -10,320.51%. Marpai's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Aclarion	-10,320.51%	-54.41%	-51.71%

Summary

Marpai and Aclarion tied by winning 8 of the 16 factors compared between the two stocks.

How does Aclarion compare to Mangoceuticals?

Mangoceuticals (NASDAQ:MGRX) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Mangoceuticals has a net margin of -4,639.13% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,639.13%	-112.00%	-104.96%
Aclarion	-10,320.51%	-54.41%	-51.71%

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Comparatively, 0.0% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mangoceuticals has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

In the previous week, Aclarion had 14 more articles in the media than Mangoceuticals. MarketBeat recorded 16 mentions for Aclarion and 2 mentions for Mangoceuticals. Aclarion's average media sentiment score of 0.99 beat Mangoceuticals' score of 0.63 indicating that Aclarion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mangoceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclarion	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 108.91%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aclarion has lower revenue, but higher earnings than Mangoceuticals. Aclarion is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	14.48	-$20.64M	-$1.49	N/A
Aclarion	$80K	110.39	-$7.23M	-$9.03	N/A

Summary

Aclarion beats Mangoceuticals on 9 of the 16 factors compared between the two stocks.

How does Aclarion compare to Advanced Biomed?

Aclarion (NASDAQ:ACON) and Advanced Biomed (NASDAQ:ADVB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Aclarion has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Advanced Biomed has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

7.5% of Aclarion shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Comparatively, 34.4% of Advanced Biomed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Advanced Biomed has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. Advanced Biomed's return on equity of 87.74% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Advanced Biomed	N/A	87.74%	64.49%

Advanced Biomed has lower revenue, but higher earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	110.39	-$7.23M	-$9.03	N/A
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	0.90

In the previous week, Aclarion had 16 more articles in the media than Advanced Biomed. MarketBeat recorded 16 mentions for Aclarion and 0 mentions for Advanced Biomed. Advanced Biomed's average media sentiment score of 1.24 beat Aclarion's score of 0.99 indicating that Advanced Biomed is being referred to more favorably in the news media.

Company	Overall Sentiment
Aclarion	Positive
Advanced Biomed	Positive

Aclarion presently has a consensus target price of $7.50, indicating a potential upside of 108.91%. Given Aclarion's stronger consensus rating and higher probable upside, research analysts clearly believe Aclarion is more favorable than Advanced Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Advanced Biomed beats Aclarion on 8 of the 15 factors compared between the two stocks.

Get Aclarion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACON vs. The Competition

Export

Metric	Aclarion	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.83M	$8.81B	$6.43B	$12.45B
Dividend Yield	N/A	1.79%	2.69%	5.22%
P/E Ratio	-0.40	22.92	23.85	24.37
Price / Sales	110.39	21.86	522.03	117.40
Price / Cash	N/A	87.48	41.27	57.13
Price / Book	0.24	5.95	10.04	6.75
Net Income	-$7.23M	$178.24M	$3.56B	$337.03M
7 Day Performance	13.97%	-0.92%	-0.82%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.66%
1 Year Performance	-46.10%	5.14%	28.88%	34.01%

Aclarion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACON Aclarion	3.5738 of 5 stars	$3.59 +2.9%	$7.50 +108.9%	-45.7%	$8.83M	$80K	N/A	7	Trending News Analyst Revision
CCM Concord Medical Services	0.4794 of 5 stars	$4.89 -0.4%	N/A	-37.6%	$21.32M	$65.85M	N/A	970
BMGL Basel Medical Group	0.9668 of 5 stars	$0.58 -2.9%	N/A	-87.1%	$11.22M	$8.90M	N/A	36	News Coverage Positive News Gap Down
MRAI Marpai	N/A	$0.43 +53.6%	N/A	-61.9%	$10.89M	$34.87M	N/A	150
MGRX Mangoceuticals	1.1353 of 5 stars	$0.55 +21.5%	N/A	-82.1%	$7.74M	$460K	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACON) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclarion (ACON) Competitors

ACON vs. CCM, BMGL, MRAI, MGRX, and ADVB

How does Aclarion compare to Concord Medical Services?

Summary

How does Aclarion compare to Basel Medical Group?

Summary

How does Aclarion compare to Marpai?

Summary

How does Aclarion compare to Mangoceuticals?

Summary

How does Aclarion compare to Advanced Biomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACON vs. The Competition

Aclarion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclarion (ACON) Competitors

ACON vs. CCM, BMGL, MRAI, MGRX, and ADVB

How does Aclarion compare to Concord Medical Services?

Which has preferable valuation & earnings, CCM or ACON?

Which has more volatility and risk, CCM or ACON?

Do insiders and institutionals have more ownership in CCM or ACON?

Does the media refer more to CCM or ACON?

Do analysts recommend CCM or ACON?

Is CCM or ACON more profitable?

Summary

How does Aclarion compare to Basel Medical Group?

Does the media prefer ACON or BMGL?

Do analysts rate ACON or BMGL?

Do institutionals & insiders hold more shares of ACON or BMGL?

Which has better earnings & valuation, ACON or BMGL?

Which has more risk and volatility, ACON or BMGL?

Is ACON or BMGL more profitable?

Summary

How does Aclarion compare to Marpai?

Which has better valuation and earnings, MRAI or ACON?

Does the media favor MRAI or ACON?

Do institutionals & insiders have more ownership in MRAI or ACON?

Which has more risk & volatility, MRAI or ACON?

Do analysts prefer MRAI or ACON?

Is MRAI or ACON more profitable?

Summary

How does Aclarion compare to Mangoceuticals?

Is MGRX or ACON more profitable?

Do insiders and institutionals hold more shares of MGRX or ACON?

Which has more risk & volatility, MGRX or ACON?

Does the media favor MGRX or ACON?

Do analysts rate MGRX or ACON?

Which has higher valuation & earnings, MGRX or ACON?

Summary

How does Aclarion compare to Advanced Biomed?

Which has more risk & volatility, ACON or ADVB?

Do insiders & institutionals have more ownership in ACON or ADVB?

Is ACON or ADVB more profitable?

Which has stronger valuation and earnings, ACON or ADVB?

Does the media refer more to ACON or ADVB?

Do analysts prefer ACON or ADVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACON vs. The Competition

Aclarion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools